| 000 | 01740 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517061840.0 | ||
| 264 | 0 | _c20160223 | |
| 008 | 201602s 0 0 eng d | ||
| 022 | _a0091-2174 | ||
| 024 | 7 |
_a10.1177/0091217415612736 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMatthew, Binoj J | |
| 245 | 0 | 0 |
_aDrug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. _h[electronic resource] |
| 260 |
_bInternational journal of psychiatry in medicine _c2015 |
||
| 300 |
_a405-11 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmphetamine-Related Disorders _xcomplications |
| 650 | 0 | 4 |
_aDiphenhydramine _xtherapeutic use |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aHaloperidol _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intramuscular |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethamphetamine _xtoxicity |
| 650 | 0 | 4 |
_aNeural Pathways _xdrug effects |
| 650 | 0 | 4 |
_aNucleus Accumbens _xdrug effects |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 | _aPatient Admission |
| 650 | 0 | 4 | _aPatient Readmission |
| 650 | 0 | 4 |
_aPsychotic Disorders _xdiagnosis |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xdrug effects |
| 650 | 0 | 4 | _aSubstance Abuse Treatment Centers |
| 650 | 0 | 4 |
_aSubstance Abuse, Intravenous _xcomplications |
| 650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
| 650 | 0 | 4 | _aTreatment Refusal |
| 700 | 1 | _aGedzior, Joanna S | |
| 773 | 0 |
_tInternational journal of psychiatry in medicine _gvol. 50 _gno. 4 _gp. 405-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/0091217415612736 _zAvailable from publisher's website |
| 999 |
_c25411546 _d25411546 |
||